Invivyd (IVVD) has had the highest return since January 1, 2025 by a US stock in the Biotechnology Industry, returning 334%.
| ASSET | % RETURN |
|---|---|
Invivyd (IVVD) | 334.04% |
Cyclo Therapeutics (CYTHW) | 251.43% |
Dominari (DOMH) | 228.57% |
Ainos (AIMDW) | 213.39% |
Quantum BioPharma (QNTM) | 197.89% |
Transcode Therapeutics (RNAZ) | 193.45% |
Compass Therapeutics (CMPX) | 133.33% |
Celularity (CELUW) | 122.6% |
Monopar Therapeutics (MNPR) | 120.27% |
Unity Biotechnology (UBX) | 111.88% |
Coeptis Therapeutics (COEP) | 103.96% |
INmune Bio (INMB) | 102.85% |
Dermata Therapeutics Inc Warrant (DRMAW) | 101.35% |
Cyclo Therapeutics (CYTH) | 98.33% |
Akero Therapeutics (AKRO) | 93.06% |
Chromocell Therapeutics (CHRO) | 91.04% |
GH Research (GHRS) | 90.07% |
Sana Biotechnology (SANA) | 83.44% |
Creative Medical Technology (CELZ) | 83.12% |
Surrozen Inc Warrant (SRZNW) | 82.56% |
GRAIL, LLC (GRAL) | 80.75% |
Genelux Corporation Common Stock (GNLX) | 79.08% |
Absci (ABSI) | 72.96% |
Mainz Biomed (MYNZ) | 70.34% |
enGene Holdings Inc Warrants (ENGNW) | 67.06% |
